STELLAR Clinical Trial
Brain Cancer Clinical Trial: Enrollment is Now Open for Patients with Recurrent Anaplastic Astrocytoma
Are you eligible?
Patients with anaplastic astrocytoma that has recurred or progressed after surgery or biopsy, radiation therapy, and chemotherapy may be eligible to participate in the STELLAR trial.
About the treatment
There are currently no targeted therapies for patients with this rare disease. Brain cancer experts at Orbus Therapeutics are conducting the STELLAR trial to evaluate the use of eflornithine oral solution — a targeted therapy — for treating recurrent anaplastic astrocytoma.
The STELLAR trial, a phase 3 clinical trial, is now recruiting participants at selected medical centers in the United States, Belgium, Canada, Germany, Italy, and the Netherlands.
Learn more about the STELLAR clinical trial below
Fill out the form below and one of our knowledgable staff will reach out to you and answer any questions about the trial you may have.
Eflornithine is an investigational product. An investigational product is one that has not been proven to be safe and effective for this use and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.